---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-109407"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2026-03-17T23:59:59+00:00"
generated_at: "2026-05-15T10:48:01.910127+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics closes exclusive worldwide license for HCW11-006; receives $7M upfront fee

## Summary
- Total upfront fee of $7.0M: $3.5M cash plus $3.5M transferable equity interest in licensee Trimmune.
- HCW eligible for development milestones, double-digit royalties on future sales, and proceeds from future transactions.
- HCW has free option to recapture Americas rights after Phase 1 in China; Phase 1 expected H1 2027.
- Trimmune granted option to license HCW9302 for China; additional payments due if option exercised.

## SEC filing metadata
- accession: 0001193125-26-109407
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2026-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000119312526109407/0001193125-26-109407-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000119312526109407/hcwb-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-109407
- JSON: https://secwatch.observer/filing/0001193125-26-109407.json
- Plain text: https://secwatch.observer/filing/0001193125-26-109407.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.